AprilBio (397030) stock
KOSDAQ · Pharmaceuticals
As of Nov 16, 9:31 AM KST
- Market cap
- KRW 327.4 billion
- As of Nov 16, 2026
- P/E
- -37.83x
- Trailing twelve months
- P/B
- 3.38x
- Latest reported equity
- P/S
- 247.86x
- Trailing twelve months
- ROE
- -8.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 327.4 billion
- As of Nov 16, 2026
- P/E
- -37.83x
- Trailing twelve months
- P/B
- 3.38x
- Latest reported equity
- P/S
- 247.86x
- Trailing twelve months
- ROE
- -8.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-37.83x
Net loss — not comparable
P/B
3.38x
P/S
247.86x
Earnings and dividend metrics▾
Earnings
EPS
-KRW 314
Earnings per share
BPS
KRW 3,515
Book value per share
ROE
-8.9%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at KRW 314 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 3,515 of net assets.
- ROE — shareholder equity shrank by 8.9% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Separate · Filed Aug 13, 2026 | — | -KRW 2.9 billion | -KRW 2 billion | — |
| Q1 2026Separate · Filed May 15, 2026 | KRW 700 million | -KRW 2.2 billion | KRW 200 million | -66.6% |
| Q3 2025Separate · Filed Nov 13, 2025 | — | -KRW 2.5 billion | -KRW 5 billion | — |
| Q2 2025Separate · Filed Aug 13, 2025 | — | -KRW 2.7 billion | -KRW 3.1 billion | — |
| Q1 2025Separate · Filed May 15, 2025 | KRW 2.2 billion | -KRW 100 million | KRW 600 million | — |
| Q3 2024Separate · Filed Nov 14, 2024 | — | -KRW 2.4 billion | -KRW 3.1 billion | — |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Separate · Filed Mar 13, 2026 | KRW 2.2 billion | -KRW 7.3 billion | -KRW 9.7 billion | -92.1% |
| FY2024Separate · Filed Mar 13, 2025 | KRW 27.5 billion | KRW 16.9 billion | KRW 20 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
- Q3 2024 is computed as 9M 2024 minus H1 2024.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 2.80%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 90 million
- Previous 20-day average 8.31%
- Net short position
- 13,000 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 1,942,906 shares
- As of Nov 13, 2026 · 7.05% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 2.80% | KRW 90 million |
| Nov 12, 2026 | 8.04% | KRW 190 million |
| Nov 11, 2026 | 9.25% | KRW 260 million |
| Nov 10, 2026 | 5.71% | KRW 130 million |
| Nov 9, 2026 | 5.55% | KRW 170 million |
| Nov 6, 2026 | 15.43% | KRW 490 million |
| Nov 5, 2026 | 16.10% | KRW 570 million |
| Nov 4, 2026 | 10.11% | KRW 270 million |
| Nov 3, 2026 | 17.90% | KRW 400 million |
| Nov 2, 2026 | 3.64% | KRW 50 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- [Amended] Share Pledge Agreement Involving a Change of Largest Shareholder(Korean)Oct 23, 2026 · Change of Largest Shareholder
- Report on Major Holdings of Shares (General Form)(Korean)Oct 23, 2026 · Major Holding Report
- Report on Major Holdings of Shares (General Form)Sep 28, 2026 · Major Holding ReportEnglish
- Results of Extraordinary General Meeting(Korean)Sep 22, 2026 · Shareholders Meeting
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Sep 18, 2026 · Insider Ownership Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Sep 17, 2026 · Insider Ownership Report
- Report on Major Holdings of Shares (Short Form)(Korean)Sep 9, 2026 · Major Holding Report
- [Amended] Resolution to Convene a Shareholders Meeting (Extraordinary General Meeting)(Korean)Sep 7, 2026 · Shareholders Meeting
Filings with a published English version open in English; the rest link to the Korean original.
AprilBio (397030) stock information
KOSDAQ
AprilBio (397030) is listed on KOSDAQ. Its market capitalization is about KRW 327.4 billion. On trailing-twelve-month earnings the P/E ratio is -37.83, and the P/B ratio is 3.38. Return on equity is -8.9%. These figures are computed in-house from official filings and are reference information only.
AprilBio — frequently asked questions
- What is the P/E ratio of AprilBio (397030)?
- On a trailing-twelve-month basis, 397030 trades at a P/E ratio of -37.83. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of AprilBio?
- 397030 has a market capitalization of about KRW 327.4 billion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.